RFA Reissuance Request AIDS Malignancy Consortium

Office of HIV and AIDS Malignancy (OHAM)

Cooperative Agreement 5 Years Funding \$18,100,000 year 1 \$96,956,954 over 5 years



BSA Mar 20, 2024

Background - HIV Epidemic


Approximately 39 million people live with HIV worldwide, and there are ~1.3 million new infections per year:

United States

- ~1.2 million people live with HIV
- ~32,000 new infections per year
- Sub Saharan Africa (SSA)
 - ~25.6 million people live with HIV
 - ~660,000 new infections per year
- Latin America
 - ~2.2 million people live with HIV
 - ~110,000 new infections per year


Cancer has been a prominent manifestation of HIV/AIDS since the beginning of the epidemic and is a leading cause of morbidity and mortality among people with HIV (PWH)

HIV and Elevated Risk of Cancer




Burden of HIV/AIDS, Cervical Cancer and Kaposi Sarcoma in Sub Saharan Africa (SSA)

HIV Incidence per 1000



UNAIDS 2022


 ~90% in low- and middle-income countries (LMICs) Kaposi Sarcoma Incidence per 100,000



Globocan 2020

- 34,270 new cases/year worldwide
- 15,086 deaths/year
- > 90 % of cases in LMICs
- Most common cancer in men <65 years of age <u>overall</u> in some countries in SSA

Cervical Cancer Incidence per 100,000




Globocan 2020

- 1st/2nd most common cancers in women in many LMICs
- 117,316 new cases/year


AMC Mission

- Develop and evaluate clinical interventions for the treatment and prevention of malignancies in people with HIV
- Conduct Phase I, II and III clinical trials of HIV-related malignancies
- Investigate the biology of these malignancies in the context of clinical trials
- Contribute specimens and clinical data to the AIDS and Cancer Specimen Resource (ACSR)

AIDS Malignancy Consortium



AMC Sites




Strengths of the AMC


- Specialized clinical expertise of investigators in studying and treating tumors in PWH.
- Success in recruiting a diverse population of patients, including underserved populations.
- Provides PWH needed access to clinical trials for cancer therapy. These patients often are marginalized, stigmatized and otherwise lack access to care.

Some Performance Parameters


- Developed 12 protocols to date in this grant cycle (the past 36 months).
- 10 protocols completed enrollment.
- 1422 patients accrued (609 ANCHOR + 813 non-ANCHOR); excludes survey, laboratory and quality of life studies.
- 17 protocols actively accruing patients.
- Approximately 63% of accrued US participants are of African-American or Hispanic origin.
- In the last 3 years, published approximately 45 papers in peer-reviewed journals.

AMC Accrual and Demographics





Anal Cancer HSIL Outcomes Research (ANCHOR) Study



Cumulative Accrual

- A randomized controlled trial to establish whether treatment of anal high grade squamous intraepithelial lesions (HSIL) is an effective strategy to prevent anal cancer.
- 10,885 participants screened and 4535 randomized to a treatment or active monitoring arm
- The results showed that the treatment of anal HSIL is effective in preventing anal cancer, which has led to change of practice guidelines.

AMC Accomplishments this Grant Cycle

- Evaluated immunotherapy approaches to solid tumors: e.g., use of ipilimumab and nivolumab in advanced solid tumors, and brentuximab vedotin, or nivolumab for Hodgkin lymphoma.
- Development and assessment of new approaches for the front-line treatment of AIDS lymphoma: e.g., ibrutinib and R-DA-EPOCH; and piloting the use of CAR-T cell therapeutic approach for refractory HIVassociated lymphoma.
- Investigated treatments with novel mechanisms of action for KS (e.g., sEphB4-HAS, nelfinavir, pomalidomide, ixazomib).
- Evaluation of the feasibility of treating ocular surface squamous neoplasia (OSSN) by surgical excision in SSA.

AMC Accomplishments this Grant Cycle (Cont.)

- Assessment of a therapeutic vaccine directed to E6 and E7 HPV 16/18 genes using electroporation.
- Evaluated HPV vaccinations to reduce the recurrence of cervical HSIL after LEEP for cervical HSIL in SSA in WLWH.
- Trained a network of clinicians in high resolution anoscopy for screening and treating anal HSIL in LATAM AMC sites.
- Assessing smoking cessation interventions in patients undergoing low dose computerized tomography of the chest for lung cancer screening.

AMC Mid-Cycle Evaluation

- Uniquely positioned to carry forward the NCI clinical agenda in HIVassociated malignancies.
- The evaluation noted that AMC contributions had significantly impacted the field in the United States and globally, including seminal practice-changing contributions.
- The evaluators highlighted the value of the infrastructure developed by the ANCHOR trial which will further continue to grow the field.
- Outstanding productivity of the disease Working Groups and the renewed focus on cutting-edge immunotherapy-based clinical trials.
- Commended the significant and laudable efforts of the Career Enhancement Program; and the development and capacity building of international clinical sites.

Evaluation Recommendations

- Formation of an External Advisory Board for periodic review of AMC's prioritization and evaluation processes.
- The AMC should increase the proportion of AMC studies being conducted in LMICs due to the burden of HIV-infection in LMICs.
- AMC should continue to facilitate greater involvement of international junior investigators and trainees, especially those from Africa in AMC studies.
- The AMC should develop and convey plans to overcome obstacles to expanding novel therapies to international sites.

Total Proposed AMC Budget

	Year 1	Year 2	Year 3	Year 4	Year 5
AMC	18,100,000	18,849,000	19,414,240	19,996,904	20,596,810
Total	96,956,954				

Source of Funds: NCI AIDS funds, apportioned by the NIH Office of AIDS Research (OAR) and targeted for AIDS research ("AIDS funds").

Difference in AMC Year One Proposed Budget from Current Budget

Estimated AMC year 5 total budget: ~ \$ 21,331,737

Proposed Year 1 Budget (AMC): \$18,100,000

Estimated AMC year 5 non-ANCHOR funds: ~ \$14,000,000

Difference from year 5 non-ANCHOR funds : \$ 4,100,000

This cost increase includes:

- ANCHOR correlative science \$1,000,000;
- Support for Data Commons platform to meet NIH mandated data-sharing responsibilities) \$1,000,000;
- Support for statistics and data analysis staff \$ 200,000
- International site support for drug sourcing, storage, distribution; imaging and radiation monitoring...etc. \$300,000;
- Adding two new International clinical sites \$300,000
- Support for the operation center to meet the growing administrative, clinical, regulatory and logistic needs of the AMC, \$800,000;
- Support for 2 more international fellows, \$80,000; and
- Inflation increase, \$420,000.

AMC Patient Costs

Core structure + patient care \$7,750,000 Cost per patient ~ \$25,800

Minimum 300 patients 30 domestic sites + 12 in SSA & Latin America

Areas Where the AMC Makes Unique Contributions

- Only group with expertise and focus on HIV/AIDS-associated cancers.
- Poised to further evaluate immunotherapy approaches for malignancies in PWH.
- Conducts preventive and therapeutic trials for Kaposi sarcoma and HPV-related precancers and cancers in PWH.
- Only NCI-supported clinical trial network to conduct interventional trials for HIV malignancies in LMIC.
- Investigation of pharmacokinetic interactions between novel anticancer drugs and antiretroviral drugs - will facilitate the inclusion of PWH on larger CTEP studies.
- Has established a network of clinicians trained in high resolution anoscopy and treating anal HSIL. This resource can be used for other key studies in this area.

Questions